Recomendaciones sobre el tratamiento de la candidiasis invasiva y otras infecciones por levaduras de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC). Actualización 2011

Pfaller, 2007, Epidemiology of invasive candidiasis: a persistent public health problem, Clin Microbiol Rev., 20, 133, 10.1128/CMR.00029-06 Almirante, 2005, Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003, J Clin Microbiol., 43, 1829, 10.1128/JCM.43.4.1829-1835.2005 Bouza, 2008, Epidemiology of candidemia in intensive care units, Int J Antimicrob Agents., 32, S87, 10.1016/S0924-8579(08)70006-2 Marr, 2000, Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption ofprophylactic fluconazole, J Infect Dis., 181, 309, 10.1086/315193 Sipsas, 2009, Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007): stable incidence but changing epidemiology of a still frequently lethal infection, Cancer., 115, 4745, 10.1002/cncr.24507 Barnes, 2007, Risks, diagnosis and outcomes of invasive fungal infections in haematopoietic stem cell transplant recipients, Br J Haematol., 139, 519, 10.1111/j.1365-2141.2007.06812.x Meunier, 2008, The First European Conference on Infections in Leukaemia -ECIL1: a current perspective, Eur J Cancer., 44, 2112, 10.1016/j.ejca.2008.07.008 Böhme, 2009, Treatment of invasive fungal infections in cancer patients--recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Ann Hematol., 88, 97, 10.1007/s00277-008-0622-5 Pappas, 2009, Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America, Clin Infect Dis., 48, 503, 10.1086/596757 Anaissie, 1996, Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature, Clin Infect Dis., 23, 964, 10.1093/clinids/23.5.964 Phillips, 1997, Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group, Eur J Clin Microbiol Infect Dis., 16, 337, 10.1007/BF01726360 Rex, 1994, A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute, N Engl J Med., 331, 1325, 10.1056/NEJM199411173312001 Kullberg, 2005, Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial, Lancet., 366, 1435, 10.1016/S0140-6736(05)67490-9 Mora-Duarte, 2002, Comparison of caspofungin and amphotericin B for invasive candidiasis. Caspofungin Invasive Candidiasis Study Group, N Engl J Med., 347, 2020, 10.1056/NEJMoa021585 Walsh, 2004, Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia, N Engl J Med., 351, 1391, 10.1056/NEJMoa040446 Kuse, 2007, Micafungin versus liposomal amphotericin B for candidaemia andinvasive candidosis: a phase III randomised double-blind trial, Lancet., 369, 1519, 10.1016/S0140-6736(07)60605-9 Queiroz-Telles, 2008, Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial, Pediatr Infect Dis J., 27, 820, 10.1097/INF.0b013e31817275e6 Pappas, 2007, Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis, Clin Infect Dis., 45, 883, 10.1086/520980 Reboli, 2007, Anidulafungin versus fluconazole for invasive candidiasis, N Engl J Med., 356, 2472, 10.1056/NEJMoa066906 Ostrosky-Zeichner, 2003, Amphotericin B: time for a new “gold standard”, Clin Infect Dis., 37, 415, 10.1086/376634 Walsh, 1999, Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group, N Engl J Med, 340, 764, 10.1056/NEJM199903113401004 Rodríguez, 2007, Impact of early central venous catheter removal on outcome in patients with candidaemia, Clin Microbiol Infect., 13, 788, 10.1111/j.1469-0691.2007.01758.x Raad, 2004, Management of central venous catheters in patients with cancer and candidemia, Clin Infect Dis., 38, 1119, 10.1086/382874 Anaissie, 1991, Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy, Am J Med., 91, 142, 10.1016/0002-9343(91)90006-J Kauffman, 1991, Hepatosplenic candidiasis: successful treatment with fluconazole, Am J Med. 1, 91, 137, 10.1016/0002-9343(91)90005-I Gokhale, 1993, Successful treatment of disseminated candidiasis resistant to amphotericin B by liposomal amphotericin B: a case report, J Cancer Res Clin Oncol., 119, 569, 10.1007/BF01372718 Sorà, 2002, Successful treatment with caspofungin of hepatosplenic candidiasis resistant to liposomal amphotericin B, Clin Infect Dis, 35, 1135, 10.1086/343748 Legrand, 2008, Adjuvant corticosteroid therapy for chronic disseminated candidiasis, Clin Infect Dis., 46, 696, 10.1086/527390 Marik, 2006, Fungal infections in solid organ transplantation, Expert Opin Pharmacother., 7, 297, 10.1517/14656566.7.3.297 Pappas, 2010, Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET), Clin Infect Dis., 50, 1101, 10.1086/651262 Kontoyiannis, 2008, Calcineurin inhibitor agents interact synergistically with antifungal agents in vitro against Cryptococcus neoformans isolates: correlation with outcome in solid organ transplant recipients with cryptococcosis, Antimicrob Agents Chemother., 52, 735, 10.1128/AAC.00990-07 Singh, 2007, Cryptococcus neoformans in organ transplant recipients: impact of calcineurin-inhibitor agents on mortality, J Infect Dis., 195, 756, 10.1086/511438 Perfect, 2010, Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america, Clin Infect Dis., 50, 291, 10.1086/649858 Del Poeta, 2000, Synergistic antifungal activities of bafilomycin A(1), fluconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformans, Antimicrob Agents Chemother., 44, 739, 10.1128/AAC.44.3.739-746.2000 Mann, 2009, Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species, Antimicrob Agents Chemother., 53, 5026, 10.1128/AAC.01031-09 Singh, 2008, Antifungal management practices in liver transplant recipients, Am J Transplant., 8, 426, 10.1111/j.1600-6143.2007.02089.x Pappas, 2006, Invasive fungal infections in low-risk liver transplant recipients: a multi-center prospective observational study, Am J Transplant., 6, 386, 10.1111/j.1600-6143.2005.01176.x Fortun, 2009, Prophylaxis with caspofungin for invasive fungal infections in high-risk liver transplant recipients, Transplantation., 87, 424, 10.1097/TP.0b013e3181932e76 Singh, 2005, Antifungal management practices and evolution of infection in organ transplant recipients with Cryptococcus neoformans infection, Transplantation., 80, 1033, 10.1097/01.tp.0000173774.74388.49 Baddour, 2005, Successful use of amphotericin B lipid complex in the treatment of cryptococcosis, Clin Infect Dis., 40, S409, 10.1086/429337 Barrett, 2003, A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations, Clin Ther., 25, 1295, 10.1016/S0149-2918(03)80125-X Sun, 2009, Lipid formulations of amphotericin B significantly improve outcome in solid organ transplant recipients with central nervous system cryptococcosis, Clin Infect Dis., 49, 1721, 10.1086/647948 Schwarz, 2006, Efficacy of amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis, Antimicrob Agents Chemother., 50, 113, 10.1128/AAC.50.1.113-120.2006 Brouwer, 2004, Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial, Lancet., 363, 1764, 10.1016/S0140-6736(04)16301-0 van der Horst, 1997, Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group, N Engl J Med., 337, 15, 10.1056/NEJM199707033370103 Bicanic, 2008, High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial, Clin Infect Dis., 47, 123, 10.1086/588792 Dromer, 2008, Major role for amphotericin B-flucytosine combination in severe cryptococcosis, PLoS One., 3, e2870, 10.1371/journal.pone.0002870 Allendoerfer, 1991, Combined therapy with fluconazole and flucytosine in murine cryptococcal meningitis, Antimicrob Agents Chemother., 35, 726, 10.1128/AAC.35.4.726 Bava, 1994, Flucytosine+fluconazole association in the treatment of a murine experimental model of cryptococcosis, Rev Inst Med Trop Sao Paulo., 36, 551, 10.1590/S0036-46651994000600013 Bicanic, 2009, Relationship of cerebrospinal fluid pressure, fungal burden and outcome in patients with cryptococcal meningitis undergoing serial lumbar punctures, AIDS., 23, 701, 10.1097/QAD.0b013e32832605fe Liliang, 2002, Use of ventriculoperitoneal shunts to treat uncontrollable intracranial hypertension in patients who have cryptococcal meningitis without hydrocephalus, Clin Infect Dis., 34, E64, 10.1086/340525 Graybill, 2000, Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups, Clin Infect Dis., 30, 47, 10.1086/313603 Chin, 1990, Pharmacokinetics of fluconazole in serum and cerebrospinal fluid in a patient with AIDS and cryptococcal meningitis, Pharmacotherapy., 10, 305 Nagappan, 2007, Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent, Clin Infect Dis., 45, 1610, 10.1086/523576 Bandettini, 2009, Voriconazole for cryptococcal meningitis in children with leukemia or receiving allogeneic hemopoietic stem cell transplant, J Chemother., 21, 108, 10.1179/joc.2009.21.1.108 Sun, 2009, Cryptococcosis in solid-organ, hematopoietic stem cell, and tissue transplant recipients: evidence-based evolving trends, Clin Infect Dis., 48, 1566, 10.1086/598936 Singh, 2005, An immune reconstitution syndrome-like illness associated with Cryptococcus neoformans infection in organ transplant recipients, Clin Infect Dis., 40, 1756, 10.1086/430606 Singh, 2005, Allograft loss in renal transplant recipients with Cryptococcus neoformans associated immune reconstitution syndrome, Transplantation., 80, 1131, 10.1097/01.tp.0000180530.17683.02 Pérez-Parra, 2009, Is Candida colonization of central vascular catheters in non-candidemic, non-neutropenic patients an indication for antifungals?, Intensive Care Med., 35, 707, 10.1007/s00134-009-1431-6 Saag, 2000, Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America, Clin Infect Dis., 30, 710, 10.1086/313757 Jarvis, 1995, Epidemiology of nosocomial fungal infections, with emphasis on Candida species, Clin Infect Dis., 20, 1526, 10.1093/clinids/20.6.1526 Vincent, 2009, International Study of the Prevalence and Outcomes of Infection in Intensive Care Units, JAMA., 302, 2323, 10.1001/jama.2009.1754 Eggimann, 2003, Epidemiology of Candida species infections in critically ill non-immunosuppressed patients, Lancet Infect Dis., 3, 685, 10.1016/S1473-3099(03)00801-6 León, 2009, Fungal colonization and/or infection in non-neutropenic critically ill patients: results of the EPCAN observational study, Eur J Clin Microbiol Infect Dis., 28, 233, 10.1007/s10096-008-0618-z León, 2009, Usefulness of the “Candida score” for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study, Crit Care Med., 37, 1624, 10.1097/CCM.0b013e31819daa14 Leroy, 2009, Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: A multicenter, prospective, observational study in France (2005-2006), Crit Care Med., 37, 1612, 10.1097/CCM.0b013e31819efac0 Marriott, 2009, Determinants of mortality in non-neutropenic ICU patients with candidaemia, Critical Care., 13, R115, 10.1186/cc7964 Holley, 2009, Temporal trends, risk factors and outcomes in albicans and non-albicans candidaemia: an international epidemiological study in four multidisciplinary intensive care units, Int J Antimicrob Agents., 33, 554.e1, 10.1016/j.ijantimicag.2008.10.035 Eggimann, 1999, Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients, Crit Care Med., 27, 1066, 10.1097/00003246-199906000-00019 Pelz, 2001, Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients, Ann Surg., 233, 542, 10.1097/00000658-200104000-00010 Garbino, 2002, Prevention of severe Candida infections in nonneutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination, Intensive Care Med., 28, 1708, 10.1007/s00134-002-1540-y Piarroux, 2004, Assessment of preemptive treatment to prevent severe candidiasis in critically ill surgical patients, Crit Care Med., 32, 2443, 10.1097/01.CCM.0000147726.62304.7F Cruciani, 2005, Prophylaxis of Candida infections in adult trauma and surgical intensive care patients: a systematic review and meta-analysis, Intensive Care Med., 31, 1479, 10.1007/s00134-005-2794-y Playford, 2006, Antifungal agents for preventing fungal infections in non-neutropenic critically ill and surgical patients: systematic review and meta-analysis of randomized clinical trials, J Antimicrob Chemother., 57, 628, 10.1093/jac/dki491 Vardakas, 2006, Antifungal prophylaxis with azoles in high-risk, surgical intensive care unit patients: a meta-analysis of randomized, placebo-controlled trials, Crit Care Med., 34, 1216, 10.1097/01.CCM.0000208357.05675.C3 Pittet, 1994, Candida colonization and subsequent infections in critically ill surgical patients, Ann Surg., 220, 751, 10.1097/00000658-199412000-00008 Rex, 1994, A Randomized Trial Comparing Fluconazole with Amphotericin B for the Treatment of Candidemia in Patients without Neutropenia, N Engl J Med., 331, 1325, 10.1056/NEJM199411173312001 DiNubile, 2007, Invasive candidiasis treated in the intensive care unit: Observations from a randomized clinical trial, J Crit Care., 22, 237, 10.1016/j.jcrc.2006.11.004 Hsu, 2010, A multicentre study to evaluate the impact of timing of caspofungin administration on outcomes of invasive candidiasis in non-immunocompromised adult patients, J Antimicrob Chemother., 65, 1765, 10.1093/jac/dkq216 Ortega, 2010, Candida spp. bloodstream infection: influence of antifungal treatment on outcome, J Antimicrob Chemother., 65, 562, 10.1093/jac/dkp495 Magill, 2006, Triazole Cross-Resistance among Candida spp.: Case Report, Occurrence among Bloodstream Isolates, and Implications for Antifungal Therapy, J Clin Microbiol., 44, 529, 10.1128/JCM.44.2.529-535.2006 Nolla-Salas, 1997, Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy. Study Group of Fungal Infection in the ICU, Intensive Care Med., 23, 23, 10.1007/s001340050286 Morrell, 2005, Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality, Antimicrob Agents Chemother., 49, 3640, 10.1128/AAC.49.9.3640-3645.2005 Garey, 2006, Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study, Clin Infect Dis., 43, 25, 10.1086/504810 Parkins, 2007, Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections, J Antimicrob Chemother., 60, 613, 10.1093/jac/dkm212 Fridkin, 2006, Changing incidence of Candida bloodstream infections among NICU patients in the United States: 1995-2004, Pediatrics., 117, 1680, 10.1542/peds.2005-1996 Stoll, 2002, Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network, Pediatrics., 110, 285, 10.1542/peds.110.2.285 Saiman, 2001, Risk factors for Candida species colonization of neonatal intensive care unit patients, Pediatr Infect Dis J., 20, 1119, 10.1097/00006454-200112000-00005 Chapman, 2003, Candida infections in the neonate, Curr Opin Pediatr., 15, 97, 10.1097/00008480-200302000-00016 Rodríguez, 2006, Candidemia in neonatal intensive care units: Barcelona, Spain. Pediatr Infect Dis J., 25, 224, 10.1097/01.inf.0000202127.43695.06 López Sastre, 2003, Neonatal invasive candidiasis: a prospective multicenter study of 118 cases, Am J Perinatol., 20, 153, 10.1055/s-2003-40008 Fernández, 2000, Candidal meningitis in neonates: a 10-year review, Clin Infect Dis., 31, 458, 10.1086/313973 Cotten, 2006, The association of third-generation cephalosporin use and invasive candidiasis in extremely low birth-weight infants, Pediatrics., 118, 717, 10.1542/peds.2005-2677 Kaufman, 2006, Patterns of fungal colonization in preterm infants weighing less than 1000 grams at birth, Pediatr Infect Dis J., 25, 733, 10.1097/01.inf.0000226978.96218.e6 Saiman, 2000, Risk factors for candidemia in Neonatal Intensive Care Unit patients. The National Epidemiology of Mycosis Survey study group, Pediatr Infect Dis J., 19, 319, 10.1097/00006454-200004000-00011 Benjamin, 2006, Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months, Pediatrics., 117, 84, 10.1542/peds.2004-2292 Karlowicz, 2000, Should central venous catheters be removed as soon as candidemia is detected in neonates?, Pediatrics., 106, E63, 10.1542/peds.106.5.e63 Chapman, 2000, Persistently positive cultures and outcome in invasive neonatal candidiasis, Pediatr Infect Dis J., 19, 822, 10.1097/00006454-200009000-00003 Steinbach, 2005, Antifungal agents in children, Pediatr Clin North Am., 52, 895, 10.1016/j.pcl.2005.02.009 Almirante, 2007, Antifungal agents in neonates: issues and recommendations, Paediatr Drugs., 9, 311, 10.2165/00148581-200709050-00004 American Academy of Pediatrics. Candidiasis. En: Pickering, L.K., editor. Red Book: 2009 Report of the Committee on Infectious Diseases. Elk Grove Village, IL: American Academy of Pediatrics; 2009.p.245-253. Pappas, 2009, Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America, Clin Infect Dis., 48, 503, 10.1086/596757 Hall, 1987, Amphotericin B dosage for disseminated candidiasis in premature infants, J Perinatol., 7, 194 Starke, 1987, Pharmacokinetics of amphotericin B in infants and children, J Infect Dis., 155, 766, 10.1093/infdis/155.4.766 Baley, 1990, Pharmacokinetics, outcome of treatment, and toxic effects of amphotericin B and 5-fluorocytosine in neonates, J Pediatr., 116, 791, 10.1016/S0022-3476(05)82674-5 Rowen, 1998, Management of neonatal candidiasis. Neonatal Candidiasis Study Group, Pediatr Infect Dis J., 17, 1007, 10.1097/00006454-199811000-00008 Butler, 1990, Amphotericin B as a single agent in the treatment of systemic candidiasis in neonates, Pediatr Infect Dis J., 9, 51, 10.1097/00006454-199001000-00012 Walsh, 1997, Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis, Antimicrob Agents Chemother., 41, 1944, 10.1128/AAC.41.9.1944 Walsh, 1999, Amphotericin B lipid complex in pediatric patients with invasive fungal infections, Pediatr Infect Dis J., 18, 702, 10.1097/00006454-199908000-00010 Scarcella, 1998, Liposomal amphotericin B treatment for neonatal fungal infections, Pediatr Infect Dis J., 17, 146, 10.1097/00006454-199802000-00013 Juster-Reicher, 2003, High-dose liposomal amphotericin B in the therapy of systemic candidiasis in neonates, Eur J Clin Microbiol Infect Dis., 22, 603, 10.1007/s10096-003-0993-4 Lee, 1992, Safety and pharmacokinetics of fluconazole in children with neoplastic diseases, J Pediatr., 120, 987, 10.1016/S0022-3476(05)81975-4 Saxen, 1993, Pharmacokinetics of fluconazole in very low birth weight infants during the first two weeks of life, Clin Pharmacol Ther., 54, 269, 10.1038/clpt.1993.147 Seay, 1995, Pharmacokinetics of fluconazole in immune-compromised children with leukemia or other hematologic diseases, Pharmacotherapy., 15, 52 Wade, 2008, Population pharmacokinetics of fluconazole in young infants, Antimicrob Agents Chemother., 52, 4043, 10.1128/AAC.00569-08 Wade, 2009, Fluconazole dosing for the prevention or treatment of invasive candidiasis in young infants, Pediatr Infect Dis J., 28, 717, 10.1097/INF.0b013e31819f1f50 Driessen, 1996, Fluconazole vs. amphotericin B for the treatment of neonatal fungal septicemia: a prospective randomized trial, Pediatr Infect Dis J., 15, 1107, 10.1097/00006454-199612000-00011 Linder, 2003, Treatment of candidaemia in premature infants: comparison of three amphotericin B preparations, J Antimicrob Chemother., 52, 663, 10.1093/jac/dkg419 Würthwein, 2005, Population pharmacokinetics of amphotericin B lipid complex in neonates, Antimicrob Agents Chemother., 49, 5092, 10.1128/AAC.49.12.5092-5098.2005 Steinbach, 2005, New antifungal agents under development in children and neonates, Curr Opin Infect Dis., 18, 484, 10.1097/01.qco.0000185986.64759.9a Seibel, 2005, Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients, Antimicrob Agents Chemother., 49, 3317, 10.1128/AAC.49.8.3317-3324.2005 Heresi, 2006, The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants, Pediatr Infect Dis J., 25, 1110, 10.1097/01.inf.0000245103.07614.e1 Benjamin, 2006, Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections, Antimicrob Agents Chemother., 50, 632, 10.1128/AAC.50.2.632-638.2006 Smith, 2009, Pharmacokinetics of an elevated dosage of micafungin in premature neonates, Pediatr Infect Dis J., 28, 412, 10.1097/INF.0b013e3181910e2d Zaoutis, 2005, The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: A propensity analysis, Clin Infect Dis., 41, 1232, 10.1086/496922 Stamos, 1995, Candidemia in a pediatric population, Clin Infect Dis., 20, 571, 10.1093/clinids/20.3.571 Blyth, 2009, Not just little adults: candidemia epidemiology, molecular characterization, and antifungal susceptibility in neonatal and pediatric patients, Pediatrics., 123, 1360, 10.1542/peds.2008-2055 Celebi, 2008, Nosocomial candidaemia in children: results of a 9-year study, Mycoses., 51, 248, 10.1111/j.1439-0507.2007.01464.x Prasad, 2008, Pediatric antifungal utilization: new drugs, new trends, Pediatr Infect Dis J., 27, 1083, 10.1097/INF.0b013e31817eeee5 Blyth, 2007, Antifungal therapy in children witn invasive fungal infections: a systematic review, Pediatrics., 119, 772, 10.1542/peds.2006-2931 Walsh, 2004, Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration, Antimicrob Agents Chemother., 48, 2166, 10.1128/AAC.48.6.2166-2172.2004 Karlsson, 2009, Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies, Antimicrob Agents Chemother., 53, 935, 10.1128/AAC.00751-08 Neeley, 2010, Voriconazole pharmacokinetics and pharmacodynamics in children, Clin Infect Dis., 50, 27, 10.1086/648679 Fisher, 2008, Caspofungin for the treatment of pediatric fungal infections, Pediatr Infect Dis J., 27, 1099, 10.1097/INF.0b013e3181937fe0 Zaoutis, 2009, A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients, Pediatrics., 123, 877, 10.1542/peds.2008-1158 Queiroz-Telles, 2008, Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial, Pediatr Infect Dis J., 27, 820, 10.1097/INF.0b013e31817275e6 Blyth, 2007, Antifungal therapy in children with invasive fungal infections: a systematic review, Pediatrics., 119, 772, 10.1542/peds.2006-2931 Presterl, 1994, Efficacy and safety of fluconazole in the treatment of systemic fungal infections in pediatric patients. Multicentre Study Group, Eur J Clin Microbiol Infect Dis., 13, 347, 10.1007/BF01974618 Schwarze, 2000, Treatment of candidal infections with fluconazole in neonates and infants, Eur J Med Res., 5, 203 Odio, 2004, Caspofungin therapy of neonates with invasive candidiasis, Pediatr Infect Dis J., 23, 1093, 10.1097/01.inf.0000145408.51526.0a Merlin, 2006, Efficacy and safety of caspofungin therapy in children with invasive fungal infections, Pediatr Infect Dis J., 25, 1186, 10.1097/01.inf.0000246844.42159.a0 Koo, 2007, Efficacy and safety of caspofungin for the empiric management of fever in neutropenic children, Pediatr Infect Dis J., 26, 854, 10.1097/INF.0b013e318067b4d1 Pasqualotto, 2008, Voriconazole plasma monitoring, Arch Dis Child., 93, 578, 10.1136/adc.2007.118844 Maertens, 2010, A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia, Pediatr Infect Dis J., 29, 415, 10.1097/INF.0b013e3181da2171 Gonzalez, 1996, Cryptococcosis in human immunodeficiency virus-infected children, Pediatr Infect Dis J., 15, 796, 10.1097/00006454-199609000-00012 Sirinavin, 2004, Mother-to-child transmission of cryptococcus neoformans, Pediatr Infect Dis J., 23, 278, 10.1097/01.inf.0000115639.43305.9b Manfredi, 1997, Liposomal amphotericin B and recombinant human granulocyte-macrophage colony-stimulating factor (rHuGM-CSF) in the treatment of paediatric AIDS-related cryptococcosis, Int J STD AIDS., 8, 406, 10.1258/0956462971920226 Wiley, 2005, Efficacy and safety of amphotericin B lipid complex in 548 children and adolescents with invasive fungal infections, Pediatr Infect Dis J., 24, 167, 10.1097/01.inf.0000153183.51258.b8 Perfect, 2010, Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America, Clin Infect Dis., 50, 291, 10.1086/649858 Pfaller, 2004, Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus, J Clin Microbiol., 42, 4419, 10.1128/JCM.42.10.4419-4431.2004 Girmenia, 2005, Invasive infections caused by Trichosporon species and Geotrichum capitatum in patients with hematological malignancies: a restropective multicenter study from Italy and review of the literature, J Clin Microbiol., 43, 1818, 10.1128/JCM.43.4.1818-1828.2005 Moretti-Branchini, 2001, Trichosporon species infection in bone marrow transplanted patients, Diagnost Microbiol Infect Dis., 39, 161, 10.1016/S0732-8893(01)00215-2 Asada, 2006, Succesful treatment of breakthrough Trichosporon ashaii fungemia with voriconazole in a patient with acute myeloid leukemia, Clin Infect Dis., 43, e39, 10.1086/505970 Moylett, 2003, Trichosporon pullulans infection in 2 patientes with chronic granulomatous disease: an emerging pathogen and review of the literature, J Allergy Clin Immnunol., 111, 1370, 10.1067/mai.2003.1522 Serena, 2006, Efficacy of voriconazole in a guinea pig model of invasive trichosporonosis, Antimicrob Agents Chemother., 50, 2240, 10.1128/AAC.00045-06 Antachopoulos, 2005, Fungemia due Trichosporon asahii in a neutropenic child refractary to amphoteriocin B. Clearance with voriconazole, J Pediatr Hematol Oncol., 27, 283, 10.1097/01.mph.0000164865.70522.d7